US biotech sector expects IPO rebound in 2026 after severe market contraction
The US biotech sector expects an IPO rebound in 2026 after a record contraction. Improved policy clarity and lower interest rates are driving renewed confidence.
Insights:
The biotechnology sector in the 
US is preparing for a potential resurgence in initial public offerings during 2026 following a historically weak performance throughout the previous year. Data indicates that only 10 biotech companies successfully entered the public markets in 2025, marking the lowest activity level in over a decade. This contraction represents a significant decline from the 26 offerings seen in 2024 and the record peak of 93 initial public offerings recorded during 2021.
US is preparing for a potential resurgence in initial public offerings during 2026 following a historically weak performance throughout the previous year. Data indicates that only 10 biotech companies successfully entered the public markets in 2025, marking the lowest activity level in over a decade. This contraction represents a significant decline from the 26 offerings seen in 2024 and the record peak of 93 initial public offerings recorded during 2021.Financial outcomes mirrored this decline in volume as total proceeds for the US biotech market fell to approximately $1.6 billion in 2025. This figure stands in stark contrast to the $16 billion raised during the 2021 market height. Despite the lack of new listings, the broader sector showed resilience in secondary markets, where the ended the 2025 calendar year with a gain of 33 percent.
US biotech market fell to approximately $1.6 billion in 2025. This figure stands in stark contrast to the $16 billion raised during the 2021 market height. Despite the lack of new listings, the broader sector showed resilience in secondary markets, where the ended the 2025 calendar year with a gain of 33 percent.
